Safety of gr2301 injection in healthy volunteers
Treatments studied
This trial tests an investigational drug called GR2301 in healthy volunteers to see if it is safe. It is a phase 1 study, which means it is the first time this drug is being given to people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a healthy adult with no major medical conditions
- Weigh at least 45 kg if you are a woman, or 50 kg if you are a man
- Have a BMI between 19 and 28
- Agree to sign the informed consent form
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an investigational medication called GR2301 in healthy adults. It aims to see how the drug behaves in the body and if it is safe, which is a first step before studying it in people with medical conditions.
This trial tests a new drug called GR2303 to see if it is safe and how the body processes it. It is for healthy adults who have not used similar drugs before.
This study tests a new injection called BPR-30221616 to see how safe it is and how people tolerate it. It is for healthy volunteers and will help find the right dose for future studies.
This is a first-in-human study of a new injected medication that may help with certain conditions. The trial is looking for healthy volunteers to check the drug's safety and how it works in the body.
This is an early-stage safety study testing a new experimental drug called REGN22044 in people with no serious health conditions. Researchers want to understand how safe the drug is, how well people tolerate it, and how the body processes it.
This trial tests a new drug called QLS2312, given as an injection, to see if it is safe and how the body handles it. It is an early study in healthy volunteers that helps decide if the drug can be studied in people with certain conditions.
Hear when a new Single Ascending Dose trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.